403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
Hunan Huateng Pharmaceutical to Showcase PEG Technologies and CDMO Manufacturing Capabilities at CPHI China 2026
(MENAFN- Hunan Huateng Pharmaceutical Co Ltd) SHANGHAI, China – June 2026 – Hunan Huateng Pharmaceutical Co., Ltd., a supplier of PEG derivatives and CDMO services for pharmaceutical intermediates and specialty chemicals, announced its participation in CPHI China 2026, which will take place from June 16–18, 2026, at the Shanghai New International Expo Center (SNIEC) in Shanghai, China.
The company will exhibit at Booth W3P16, where representatives will meet with pharmaceutical manufacturers, biotech companies, sourcing professionals, and international partners to discuss developments in PEG chemistry, pharmaceutical raw materials, and custom manufacturing solutions.
CPHI China remains one of the pharmaceutical industry’s key events for supply chain collaboration, technology exchange, and global sourcing. At this year’s exhibition, Huateng Pharma will present its manufacturing capabilities supporting projects from early-stage R&D through commercial production, with a focus on high-purity PEG derivatives and custom CDMO services.
The company’s PEG portfolio includes GMP-grade PEG derivatives available from gram-scale research quantities to 100 kg production scale, supporting applications across drug delivery systems, long-acting therapeutics, conjugation chemistry, and advanced pharmaceutical formulations.
Huateng Pharma’s product offerings include:
Polydispersed PEGs with molecular weights ranging from 200 Da to 43,000 Da
Monodispersed PEGs with units ranging from 1 to 48
Multi-arm PEGs designed for advanced pharmaceutical and material science applications
Alongside PEG technologies, Huateng Pharma provides CDMO solutions for pharmaceutical intermediates, cosmetic ingredients, and specialty chemicals, supporting customers with process development, scale-up, and customized manufacturing requirements.
Representative manufacturing capabilities include products such as Methacrylonitrile (CAS 126-98-7), Diethyl chloromalonate (CAS 14064-10-9), Tetrahydrocurcumin (CAS 36062-04-1), Piroctone olamine (CAS 68890-66-4), and other specialty intermediates serving pharmaceutical and industrial applications.
CEO Dr. Deng will attend the event and welcomes discussions with industry professionals regarding collaboration opportunities, manufacturing partnerships, and supply chain solutions for pharmaceutical and specialty chemical development.
“Industry exhibitions such as CPHI China provide valuable opportunities to exchange technical knowledge and strengthen global partnerships,” said Dr. Deng, CEO of Hunan Huateng Pharmaceutical Co., Ltd. “We look forward to meeting industry partners and discussing how scalable manufacturing and PEG technologies can support evolving development needs.”
Event Details
Event: CPHI China 2026
Date: June 16–18, 2026
Venue: Shanghai New International Expo Center (SNIEC), Shanghai, China
Booth: W3P16
The company will exhibit at Booth W3P16, where representatives will meet with pharmaceutical manufacturers, biotech companies, sourcing professionals, and international partners to discuss developments in PEG chemistry, pharmaceutical raw materials, and custom manufacturing solutions.
CPHI China remains one of the pharmaceutical industry’s key events for supply chain collaboration, technology exchange, and global sourcing. At this year’s exhibition, Huateng Pharma will present its manufacturing capabilities supporting projects from early-stage R&D through commercial production, with a focus on high-purity PEG derivatives and custom CDMO services.
The company’s PEG portfolio includes GMP-grade PEG derivatives available from gram-scale research quantities to 100 kg production scale, supporting applications across drug delivery systems, long-acting therapeutics, conjugation chemistry, and advanced pharmaceutical formulations.
Huateng Pharma’s product offerings include:
Polydispersed PEGs with molecular weights ranging from 200 Da to 43,000 Da
Monodispersed PEGs with units ranging from 1 to 48
Multi-arm PEGs designed for advanced pharmaceutical and material science applications
Alongside PEG technologies, Huateng Pharma provides CDMO solutions for pharmaceutical intermediates, cosmetic ingredients, and specialty chemicals, supporting customers with process development, scale-up, and customized manufacturing requirements.
Representative manufacturing capabilities include products such as Methacrylonitrile (CAS 126-98-7), Diethyl chloromalonate (CAS 14064-10-9), Tetrahydrocurcumin (CAS 36062-04-1), Piroctone olamine (CAS 68890-66-4), and other specialty intermediates serving pharmaceutical and industrial applications.
CEO Dr. Deng will attend the event and welcomes discussions with industry professionals regarding collaboration opportunities, manufacturing partnerships, and supply chain solutions for pharmaceutical and specialty chemical development.
“Industry exhibitions such as CPHI China provide valuable opportunities to exchange technical knowledge and strengthen global partnerships,” said Dr. Deng, CEO of Hunan Huateng Pharmaceutical Co., Ltd. “We look forward to meeting industry partners and discussing how scalable manufacturing and PEG technologies can support evolving development needs.”
Event Details
Event: CPHI China 2026
Date: June 16–18, 2026
Venue: Shanghai New International Expo Center (SNIEC), Shanghai, China
Booth: W3P16
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
More Story
Comments
No comment